Celldex Therapeutics, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CLDX
  • 1d-0.46%
  • 1w-3.82%
  • 1m-7.00%
  • 1y28.99%
ATH
  • ATH Price$3,015.00
  • ATH Date2000-03-06
  • % since ATH-98.70%
  • % to ATH7,616.92%
ATL
  • ATL Price$1.55
  • ATL Date2020-03-20
  • % from ATL2,420.65%
  • Last Low Price$1.55
  • Last Low Date2020-03-20
  • % From Last Low2,420.65%
IPO
  • IPO Price$4.94
  • % Current ROI USD791.29%
  • ATH Price$3,015.00
  • % ROI ATH 19,451,612.90%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CLDX"]

Key Data [addtoany]

Current price $39.07
Sector Healthcare
Industry Biotechnology
Today's High/Low $40.12/$38.69
Volume 389,234.00
Previous Close $39.25
52 Week High/Low $53.18/$22.11
Market Cap 2,577,353,984.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-3.09
Annualized Dividend $0
$39.07
[addtoany]

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.
The company’s clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company’s proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc.
with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity